Affiliation:
1. University of California, Davis Medical Center Sacramento California USA
2. University of California San Francisco School of Pharmacy San Francisco California USA
3. University of California School of Medicine Sacramento California USA
4. University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado USA
5. Anticoagulation/Cardiology University of Colorado Hospital Aurora Colorado USA
6. Wesley Medical Center Wichita Kansas USA
Abstract
AbstractAnticoagulant therapy is commonly associated with a high incidence of avoidable adverse events, especially in the acute care setting. This has led to several initiatives by key national health care stakeholders, including specific attention to The Joint Commission's National Patient Safety Goals, to improve anticoagulation management. The subject of special populations has long been identified as challenging by clinicians with the use of anticoagulants. This is driven in part by numerous variables that can contribute to hard outcomes such as bleeding, thrombosis, length of stay, hospital re‐admission, morbidity, and mortality. Despite the notable effort to improve the use of anticoagulants with numerous clinical trials, guidelines, guidance statements, and other sources of published evidence, notable difficulties continue to challenge practitioners in managing this class of medications. This is especially the case with very diverse critically ill populations where countless variables exist, many of which were never explored in trials or have historically been frequently excluded. Trials evaluating anticoagulation therapy often can only account for small portions of variables that may affect thrombosis and hemostasis, and study methods often do not reflect the constantly changing dynamic conditions seen in unique critically ill patients. Clinicians providing care to the numerous critically ill populations are faced with conditions that lead to relatively small therapeutic windows, which makes designing safe optimal anticoagulation management plans difficult when dealing with complex patients and mechanical support devices. The approach to crafting a successful management plan for anticoagulant therapy must incorporate the numerous variables that are continuously assessed and revised during the patient's time in the intensive care unit. We explore considerations and approaches when developing, assessing, and implementing an individualized or precision‐based management plan that involves the use of anticoagulants in the critically ill. The skills and thought process provided will assist clinicians in managing this unique, variable, and challenging population.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Precision medicine in the ICU: One size fits one patient;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-10-16
2. Developing precision‐based multidisciplinary pharmacotherapy management plans in the critically ill;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-09-29